The oncology clinical trials market is witnessing significant growth as increasing cancer prevalence, advancements in clinical research technologies, and the rising adoption of personalized treatment approaches continue to accelerate the development of innovative cancer therapies. The global oncology clinical trials market size was valued at USD 32.5 billion in 2025 and is projected to grow from USD 34.5 billion in 2026 to USD 58.9 billion by 2033, at a CAGR of 7.9% from 2026 to 2033. The market in North America dominated with a revenue share of 50.6% in 2025.

The growth of the oncology clinical trials market is primarily driven by technological advancements, rising cancer incidence, and improvements in personalized medicine and cell & gene therapies. Increasing investments in oncology research, growing demand for targeted therapies, and the development of advanced treatment approaches are supporting the expansion of clinical trial activities. Researchers and pharmaceutical companies are increasingly focusing on precision medicine, immunotherapies, and innovative cancer treatment solutions to improve patient outcomes and accelerate drug development processes.

The increasing complexity of cancer therapies has also encouraged the adoption of advanced clinical trial designs, digital health technologies, and data-driven research methodologies. These advancements are helping improve patient recruitment, trial efficiency, and regulatory compliance while enabling faster development of novel oncology treatments. As pharmaceutical companies, biotechnology firms, and research organizations continue expanding oncology pipelines, the demand for efficient and technologically advanced clinical trial solutions is expected to rise through 2033.

Download a free sample copy of the Oncology Clinical Trials market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

Regional analysis indicates that North America dominated the oncology clinical trials market, accounting for the largest revenue share of 50.6% in 2025. The region’s leadership is supported by strong healthcare infrastructure, significant investments in cancer research, presence of leading pharmaceutical and biotechnology companies, and increasing adoption of advanced clinical research methodologies. Furthermore, Asia Pacific is expected to register the highest CAGR from 2026 to 2033, driven by rising healthcare investments, increasing cancer burden, expanding clinical research capabilities, and growing participation in oncology trials.
Based on phase type, the Phase III segment held the largest market share of 54.3% in 2025. Phase III clinical trials play a crucial role in evaluating the safety, effectiveness, and overall benefits of oncology treatments before regulatory approval. The increasing number of late-stage cancer drug development programs and growing investments in large-scale clinical studies are contributing to the segment’s leading position.
Based on study design, the interventional studies segment held the largest market share in 2025. The dominance of this segment is attributed to the increasing requirement for evaluating new oncology therapies, treatment combinations, and advanced therapeutic approaches through controlled clinical investigations. Growing adoption of innovative trial methodologies is further supporting the expansion of interventional oncology studies.
Based on indication, the lung cancer segment held the largest market share in 2025. The high prevalence of lung cancer, increasing focus on targeted therapies, and continuous research activities for improving diagnosis and treatment options are driving the demand for oncology clinical trials related to lung cancer.
By country, the U.S. held the largest market share in 2025. The country’s leading position is supported by advanced healthcare infrastructure, high investment in cancer research, strong presence of pharmaceutical companies, and availability of advanced clinical trial networks. The growing focus on innovative cancer therapies and precision medicine continues to strengthen oncology research activities across the country.

Key Companies & Market Share Insights

The oncology clinical trials market remains highly competitive, with key players focusing on strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to strengthen their market presence. Companies are investing in advanced clinical research platforms, improving trial management capabilities, and expanding their global research networks to accelerate oncology drug development.

Industry participants are increasingly focusing on improving patient recruitment, enhancing trial efficiency, and supporting complex oncology studies involving personalized medicine, cell & gene therapies, and targeted treatments. Strategic collaborations between research organizations, clinical trial providers, and oncology networks are helping expand access to advanced clinical studies and improve treatment development processes.

START Center for Cancer Research continues to strengthen its position in oncology clinical research by expanding early-phase oncology clinical trial capabilities. In May 2025, the START Center for Cancer Research collaborated with OneOncology to expand the reach of early-phase oncology clinical trials by establishing new research sites within community oncology practices across the U.S., enabling more patients to participate in these studies outside academic institutions. These research sites will be integrated into the START Center's existing infrastructure to accelerate study initiation, ensure consistent process implementation, and improve data quality in early-phase clinical trials.

Other leading market participants are focusing on expanding clinical trial networks, strengthening research partnerships, and adopting advanced technologies to improve oncology trial outcomes. These strategic initiatives are expected to support innovation, enhance research accessibility, and improve the efficiency of cancer treatment development.

With rising cancer incidence, increasing adoption of personalized medicine, advancements in cell & gene therapies, and growing investments in oncology research, the oncology clinical trials market is expected to experience steady growth through 2033. Companies that focus on technological innovation, strategic collaborations, and efficient clinical research solutions are expected to benefit from emerging opportunities in cancer treatment development.

Key Oncology Clinical Trials Companies:

Astrazeneca
Merck & Co., Inc.
IQVIA
Gilead Sciences Inc.
F. Hoffmann-La Roche Ltd.
Parexel International Corporation
Charles River Laboratories
Syneos Health
Medpace
Labcorp Drug Development
ICON plc
Thermo Fisher Scientific (PPD)
WuXi AppTec

Grand View Research offers

Focused market intelligence reports on specific geographies or high-growth segments.
Extended forecast timelines for long-term planning.
Competitor Benchmarking and Supply Chain Analysis
Inclusion of regulatory and policy assessments.
Inclusion of custom data models, KPIs, or applications unique to your business
Specific high-impact Data Decks and Tables to support effective decision making
And much more…

Oncology Clinical Trials Market Trends Shaped by Advanced Drug Development

The global oncology clinical trials market size was valued at USD 32.5 billion in 2025 and is projected to grow from USD 34.5 billion in 2026 to USD 58.9B